In HER2-positive breast cancer, pertuzumab is added to trastuzumab and docetaxel in the neoadjuvant setting based primarily on which trial?
- A HERA trial
- B CLEOPATRA trial
- C NeoSphere trial ✓
- D KATHERINE trial
Correct answer: C. NeoSphere trial
Explanation
The NeoSphere trial demonstrated that adding pertuzumab to trastuzumab plus docetaxel in the neoadjuvant setting significantly increased pathological complete response (pCR) rates from 29% to 46% in HER2-positive early breast cancer, leading to its approval in this setting. The CLEOPATRA trial established pertuzumab benefit in metastatic HER2-positive disease, the HERA trial established adjuvant trastuzumab, and the KATHERINE trial showed adjuvant T-DM1 after neoadjuvant failure.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.